Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Dungo, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Dungo, M.

Calcium Plus Vitamin D Supplementation, 25-Hydroxyvitamin D, and Breast Cancer Risk

Rowan T. Chlebowski, MD, PhD, Deepu Madduri, MD, and Maria Dungo, MD

From the Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, and St. Mary's Medical Center, Long Beach, CA

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Rowan T. Chlebowski, MD, PhD, Chief, Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W Carson St, Torrance, CA, 90502; e-mail: rchlebowski{at}gmail.com

Overview: Breast cancer has been the focus of chemoprevention efforts.1 Based on findings from observational studies, higher calcium intake, specifically higher vitamin D intake, and higher 25-hydroxyvitamin D levels have been associated with lower breast cancer risk in some reports. Supplementation with these agents has been proposed as a breast cancer risk reduction strategy.